Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2015

 

 

PRESBIA PLC

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-36824   98-1162329

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

120/121 Baggot Street Lower

Dublin 2 Ireland

(Address of Principal Executive Offices)(Zip Code)

+353 (1) 659 9446

Registrant’s Telephone Number

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)    On March 3, 2015, the Board of Directors (the “Board”) of Presbia PLC (the “Company”) appointed Robert J. Cresci to the Board. The Board increased its size from six to seven members and appointed Mr. Cresci to fill the vacancy. Mr. Cresci has been elected to serve a term expiring at the Company’s 2015 annual meeting of shareholders. Mr. Cresci is expected to serve on the Board’s Audit Committee, provided, however, that this determination has not yet been made.

On March 3, 2015, the Company issued a press release announcing the appointment of Mr. Cresci to the Board. A copy of the press release is filed with this Form 8-K as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

  

Description

99.1    Press Release of Presbia PLC dated March 3, 2015.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

PRESBIA PLC
By:

/s/ Richard Fogarty

Name: Richard Fogarty
Title: Chief Accounting Officer

Dated: March 3, 2015

EX-99.1

Exhibit 99.1

 

LOGO

Mar 3, 2015

Presbia Announces the Appointment of Robert J. Cresci to the Board

DUBLIN—(BUSINESS WIRE)—Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced today that it has appointed Robert J. Cresci to serve on its Board of Directors. Mr. Cresci has been a Managing Director of Pecks Management Partners Ltd., an investment management firm, since 1990.

“Mr. Cresci brings extensive expertise related to growth companies from his experience with Pecks Management Partners, and serving on other public and private company boards of directors. He will also provide Presbia with significant knowledge regarding accounting issues and public company matters,” said Todd Cooper, President and CEO of Presbia.

Mr. Cresci’s biography can be found on our website at www.presbia.com.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

Presbia PLC

Monica Yamada, 323-860-4903

[email protected]

Source: Presbia PLC

News Provided by Acquire Media